CJC-1295 with DAC
CJC-1295 with DAC

Home

/

Shop

/

CJC-1295 with DAC

CJC-1295 with DAC
CJC-1295 with DAC
CJC-1295 with DAC
CJC-1295 with DAC
CJC-1295 with DAC
CJC-1295 with DAC

CJC-1295 with DAC

£19.00Sold out
Out of stock
Size
1
ABOUT THIS COMPOUND
Description

CJC-1295 with DAC from Super Human Peptides UK is a highly advanced, synthetic Growth Hormone-Releasing Hormone (GHRH) analogue. While standard GHRH analogues are destroyed by enzymes within minutes, this specific sequence features a revolutionary structural modification known as a Drug Affinity Complex (DAC). In laboratory research, CJC-1295 with DAC serves as a premier model for investigating sustained, long-term elevations in Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1).

Researchers utilize this peptide because the DAC component (a maleimidopropionic acid linker) actively binds to circulating serum albumin immediately upon entering the bloodstream. This bioconjugation physically shields the peptide from enzymatic degradation, extending its half-life from mere minutes to up to 8 days. Rather than creating short, intense pulses of growth hormone, this extended half-life creates a continuous, elevated "bleed" of GH.

Produced under GMP-compliant conditions and verified for 99% purity or higher, CJC-1295 with DAC is an elite tool for advanced preclinical research into severe GH deficiencies, lipodystrophy, and chronic systemic recovery.

WarningFor laboratory research use only. Not for human consumption.
Key Features
  • —Albumin Bioconjugation: Features a DAC linker that binds to natural blood proteins, shielding the peptide from rapid destruction.
  • —Massive Half-Life Extension: Extends the active biological half-life to approximately 6-8 days following a single administration.
  • —Continuous GH Bleed: Generates a sustained, non-pulsatile elevation of Growth Hormone and IGF-1, contrasting the natural pulsatile rhythm of the pituitary gland.
  • —GHRH Analogue: Contains a highly modified 29-amino-acid sequence (tetrasubstituted) to prevent early cleavage by the DPP-4 enzyme.
  • —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
  • —Quality Standard: GMP / ISO certified manufacturing.
Research Focus
  • —Pharmacokinetics of Bioconjugation: Studying how the reactive maleimide group covalently bonds to the free thiol of Cys34 on human serum albumin to achieve extreme stability.
  • —Sustained IGF-1 Modeling: Measuring the downstream, dose-dependent, and continuous elevation of Insulin-like Growth Factor 1 in the liver over a prolonged 7-to-14-day observation window. Pulsatile vs.
  • —Continuous GH Secretion: Investigating the physiological differences and potential receptor desensitization when exposing tissues to a constant GH bleed versus natural, episodic pulses.
  • —Lipodystrophy and Visceral Fat: Preclinical models exploring the continuous mobilization and oxidation of visceral adipose tissue driven by permanently elevated basal metabolic rates.
  • —Systemic Atrophy Recovery: Evaluating the preservation of lean muscle mass and the acceleration of protein synthesis in chronic wasting models.
Published Research and Study Findings

CJC-1295 with DAC was developed by the Canadian biotechnology company ConjuChem to solve the fundamental problem of peptide instability. Natural GHRH is destroyed by enzymes almost instantly, making it useless for long-term modeling. By engineering the Drug Affinity Complex technology, ConjuChem created a peptide that effectively hitchhikes on the body's own blood cells.

In landmark clinical and laboratory modeling, the results of this bioconjugation were unprecedented. In foundational studies, a single dose of CJC-1295 with DAC was shown to increase mean plasma GH concentrations by 2- to 10-fold for over 6 days, and it increased circulating IGF-1 levels by 1.5- to 3-fold for up to 14 days.

Because it uniquely alters the rhythm of the pituitary gland—forcing a sustained release rather than a temporary spike—it remains a highly specialized and heavily studied compound in modern endocrinology and anti-aging research.

NoteAll findings are derived from laboratory and non-clinical research settings.
Representative Scientific References
  • 1.Teichman, S.L. et al., "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults," The Journal of Clinical Endocrinology & Metabolism, 2006.
  • 2.Ionescu, M. et al., "Sustained efficacy and safety of a long-acting growth hormone-releasing hormone preparation (CJC-1295) in patients with HIV-lipodystrophy," Clinical Infectious Diseases, 2006.
  • 3.Jette, L. et al., "Human growth hormone-releasing hormone (hGHRH) 1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats," Endocrinology, 2005.
  • 4.Sackmann-Sala, L. et al., "Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog," Pituitary, 2009.
Technical data
Specifications
Purity
≥99%, HPLC verified
Form
Lyophilised white powder
Molecular formula
See batch COA
Molecular weight
See batch COA
SKU
SHP-CJCDAC-002
Research category
Secretagogues
Storage
-20°C, protected from light
Reconstitution
Reconstitute with bacteriostatic water; swirl gently, do not shake
Research use
In-vitro laboratory research only. Not for human consumption.
Common questions
Frequently asked questions
CJC-1295 with DAC is a synthetic GHRH analogue fitted with a Drug Affinity Complex that binds serum albumin, extending its half-life from minutes to roughly eight days. It is supplied as a lyophilised powder.
It is used in growth hormone deficiency models and in studies requiring sustained elevation of growth hormone and IGF-1 rather than the short pulses produced by unmodified GHRH fragments.
CJC-1295 with DAC is supplied at ≥99% purity, verified by HPLC with mass-spectrometry identity confirmation. Testing is carried out per batch rather than per product line, so the figures on your certificate of analysis relate to the exact lot in your vial.
Store the sealed vial at -20°C, protected from light. Once reconstituted, the solution should be kept refrigerated at 2-8°C, protected from light, and treated as a short-lived working preparation rather than a long-term stock.
CJC-1295 with DAC is supplied lyophilised. Reconstitute with bacteriostatic water; swirl gently, do not shake, and allow the powder to dissolve fully before use. Direct the solvent down the inside wall of the vial rather than onto the pellet, and record the volume used so working concentrations can be calculated. This applies to in-vitro laboratory work only.
The peptide backbone is the same; the DAC component is what separates them. With DAC, albumin binding extends the half-life to around eight days and produces a sustained signal. Without DAC, the active window is roughly 30 minutes and the release pattern stays pulsatile, which is closer to physiological secretion.
Yes. A certificate of analysis covering HPLC purity and mass-spectrometry identity is available for every batch of CJC-1295 with DAC. Each vial carries a batch number on its label, and quoting that number lets us send you the certificate that matches the material you hold rather than a generic example.
Exact mass data for CJC-1295 with DAC is quoted on the certificate of analysis issued with the batch you receive, since figures vary slightly by production lot. Contact us before ordering if you need the values in advance.
CJC-1295 with DAC ships from the UK to UK research addresses, with tracked dispatch and insulated packaging. It is sold for in-vitro laboratory research only: it is not a medicine, not a supplement, and not for human or veterinary consumption. Orders are accepted on the basis that the buyer is a qualified researcher.